Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.

ABSTRACT:

Background

Osimertinib-the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib demonstrated central nervous system activity in patients with brain metastasis; however, its efficacy against other distant metastatic organs, including bone and liver, remains unclear. Therefore, we retrospectively analyzed the clinical efficacy of osimertinib in these patients in comparison to other EGFR-TKIs.

Methods

Clinical data of patients with advanced NSCLC receiving gefitinib/erlotinib (n = 183), afatinib (n = 55), or osimertinib (n = 150) at five medical institutions were retrospectively assessed for progression-free

SUBMITTER: Gen S 

PROVIDER: S-EPMC9195197 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature